Design Therapeutics Inc
Gesloten
11 5.16
Overzicht
Wijziging aandelenprijs
24u
Min
10.82
Max
11
Inkomsten | -1.6M -18M |
|---|---|
EPS | -0.29 |
Werknemers | 54 |
EBITDA | -1.5M -20M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +78.67% upside |
Volgende Winsten | 5 aug 2026 |
|---|
Marktkapitalisatie | -135M 665M |
|---|---|
Vorige openingsprijs | 5.84 |
Vorige sluitingsprijs | 11 |
Design Therapeutics Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Design Therapeutics Inc Prognose
Koersdoel
By TipRanks
78.67% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 19.6 USD 78.67%
Hoogste 22 USD
Laagste 15 USD
Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Design Therapeutics Inc
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.